hotspot -WSS

hotspot

author：comprehensive 2025-10-01 00:46:02 - browse：49611

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Experts study whether long Covid risk adds up with each reinfection

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

WHO recommends second malaria vaccine

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Health Care Service Corp to buy Cigna Medicare Advantage plans

Stop Congress from blocking public access to science

6 solutions to address cancer drug shortages and others

focus

hotspot

leisure time

Continuity nursing helped my family in our darkest PICU moments

Wegovy leads to weight loss. Can it treat depression, too?

How to save PrEP access — and even expand it

Wegovy leads to weight loss. Can it treat depression, too?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Syphilis numbers in the United States reach record heights

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CRISPR base editing slashes cholesterol levels in monkeys

leisure time

Syphilis numbers in the United States reach record heights

Will an HIV vaccine ever be a reality?

FTC sues over Novant Health acquisition of two N.C. hospitals

Health Care Service Corp to buy Cigna Medicare Advantage plans

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Study points to new risk in gene therapy death of Terry Horgan

hotspot

entertainment

focus

entertainment